IGeneX Overview
- Founded
-
1991

- Status
-
Acquired/Merged
- Employees
-
44

- Latest Deal Type
-
M&A
- Financing Rounds
-
5
IGeneX General Information
Description
Provider of laboratory and research services intended for private physicians, hospitals and other clinical laboratories. The company's services include laboratory research and testing in a comprehensive way to test relevant strains of tick-borne pathogens including those pathogens and different treatment paths, thereby enabling patients to make a timely diagnosis for starting the right treatment.
Contact Information
Website
www.igenex.com
Ownership Status
Acquired/Merged
(Operating Subsidiary)
(Operating Subsidiary)
Financing Status
Formerly PE-Backed
Primary Industry
Laboratory Services (Healthcare)
Other Industries
Other Healthcare Services
Parent Company
Primary Office
- 556 Gibraltar Drive
- Milpitas, CA 95035
- United States
+1 (800) 000-0000
IGeneX Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
IGeneX Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Financing
Details
Provider of laboratory and research services intended for private physicians, hospitals and other clinical laboratories.
Laboratory Services (Healthcare)
Milpitas, CA
44
As of 2023
000000&0
IGeneX Competitors (3)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Genoma Group | Corporate Backed or Acquired | Rome, Italy | 000 | 000000&0 | ||
000000 00000000000 | Private Equity-Backed | Asheville, NC | 000 | 0000 | 000000000 | |
0000 000000000000 | Corporation | Salt Lake City, UT | 0000 |
IGeneX Patents
IGeneX Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
AU-2003265467-A1 | Assay for detection of antigen in bodily fluid | Inactive | 16-Aug-2002 | 000000000000 | |
AU-2003265467-A8 | Assay for detection of antigen in bodily fluid | Inactive | 16-Aug-2002 | 000000000000 | |
US-20040033623-A1 | Using the presence of borellia proteins in urine, cerebral spinal and/or synovial fluids to diagnose lyme disease | Inactive | 16-Aug-2002 | 000000000000 | 0 |
AU-4001199-A | Improved methods for detecting a target nucleic acid fragment | Inactive | 21-May-1998 | 0000000000 | |
EP-1080228-A1 | $i(in situ) hybridization method for detecting target nucleic acid | Active | 18-May-1998 | C12Q1/6841 |
IGeneX Executive Team (4)
Name | Title | Board Seat | Contact Info |
---|---|---|---|
Jyotsna Shah Ph.D | Chief Executive Officer, President & Laboratory Director | ||
Tom Paskert | Chief Financial Officer | ||
Sudhir Shah | Board Member & Treasurer |
IGeneX Board Members (2)
Name | Representing | Role | Since |
---|---|---|---|
000000 0000 | IGeneX | Board Member & Treasurer | 000 0000 |
IGeneX Signals
IGeneX Former Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|